Comparative Pharmacology
Head-to-head clinical analysis: LEVOLET versus THYROLAR 0 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOLET versus THYROLAR 0 5.
LEVOLET vs THYROLAR-0.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levolet (levothyroxine) is a synthetic thyroid hormone that replaces endogenous thyroxine (T4). It is converted to triiodothyronine (T3) in peripheral tissues, which binds to thyroid hormone receptors to regulate gene expression, increasing metabolic rate and protein synthesis.
Thyroid hormone replacement; L-thyroxine (T4) is converted to active triiodothyronine (T3) which binds to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate and oxygen consumption.
Levofloxacin 500 mg orally or intravenously once daily for 5-14 days depending on indication.
Initial dose 0.5 tablets (30 mg T4/7.5 mg T3) orally once daily, titrated every 2-4 weeks based on TSH, free T4, and free T3 levels; usual maintenance 0.5-2 tablets (30-120 mg T4/7.5-30 mg T3) once daily.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; shorter in patients with hepatic impairment.
For liothyronine (T3): approximately 1.5-2.5 days; for levothyroxine (T4): approximately 6-7 days. In hyperthyroidism, half-life may be shortened; in hypothyroidism, prolonged.
Renal: 70-80% unchanged, biliary/fecal: 20-30% as metabolites.
Renal (approximately 40-50% as unchanged drug and conjugates), fecal (approximately 20-30% via biliary elimination), with the remainder metabolized and eliminated via urine and feces.
Category C
Category C
Thyroid Hormone
Thyroid Hormone